Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The clearance rate, or the rate at which the carrier protein is broken down, for GHBP alone is much faster than when it is bound to its ligand. Additionally, current literature provides evidence that the carrier-protein prolongs the half-life of growth hormone through its binding with the ligand. One purpose of GHBP can be inferred: to maintain the level of GH in the blood, as roughly half of its concentration is complexed with GHBP. Yet this could be confounded by the fact that GH binding to GHBP prevents the ligand from binding to GHR and ultimately proteolytic activity. Another function is that GHBP displays competitive inhibition for GH against the GHR receptor. Studies elucidate another aspect of GHBP physiological role: The proteolytic cleavage activity that forms GHBP ultimately regulates GHR production in humans as well as rats. If there is low GHBP concentration then there are high levels of GHR expression. Conversely, high levels of GHBP protein show negative correlation with levels of growth hormone receptor expression.
Aesculin (C21H24O13), occurring in horse-chestnut and California buckeye, and daphnin, occurring in Daphne alpina, are isomeric; the former hydrolyzes to glucose and aesculetin (C9H6O4 — 6,7-dihydroxycoumarin), the latter to glucose and daphnetin (7,8-dihydroxycoumarin). Fraxin, occurring in Fraxinus excelsior, hydrolyzes to glucose and fraxetin (also known as 7,8-dihydroxy-6-methoxycoumarin) Flavone or benzo-7-pyrone derivatives are numerous; in many cases they (or the non-sugar part of the molecule) are vegetable dyes. Rhamnetin, a splitting product of the glucosides of Rhamnus, is monomethyl quercetin; fisetin, from Rhus cotinus, is monoxyquercetin; chrysin is phenyl-dihydroxybenzopyrone. Saponarin, a glucoside found in Saponaria officinalis, is a related compound. Strophanthin is the name given to two different compounds, g-strophanthin (ouabain) obtained from Strophanthus gratus and k-strophanthin from Stroph. kombé.
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
As a member of Team X, Logan was given false memory implants. Eventually breaking free of this mental control, he joined the Canadian Defense Ministry. Logan was subsequently kidnapped by the Weapon X program, where he was held captive and made a subject of experiments; the program fused adamantium onto his bones, before he escaped. James and Heather Hudson helped him recover his humanity following his escape, and Logan began work as an intelligence operative for the Canadian government's Department H. He becomes Wolverine, one of Canada's first superheroes. In his first mission, he is dispatched to stop the destruction caused by a brawl between the Hulk and the Wendigo. Professor Charles Xavier recruits Wolverine to a new iteration of his superhero-mutant team, the X-Men. He competes with Cyclops for the affection of Jean Grey. While his teammates often distrust him, Wolverine is invaluable in rescuing the others and defeating their enemies, particularly in their conflict with the Hellfire Club; due to their influence, Jean transforms into the Dark Phoenix and apparently sacrifices herself, temporarily ending the love triangle involving her, Wolverine, and Cyclops. Wolverine becomes engaged to Mariko Yashida, a wealthy businesswoman whose father is head of the Clan Yashida criminal organization, and battles the Hand, a secret society of ninjas. However, she breaks off the engagement, under the influence of a member of the Hellfire Club. He battles Sabretooth, and discovers that he had multiple encounters with him that his traumatic amnesia concealed.
Sources: en.wikipedia.org
The researchers have set out to answer possible questions from teachers using the program, highlight some minimum recommended training requirements for the software, suggest some "hints and tips" for teaching ideas, explain the importance of performing more studies / trials with the program, overview randomised controlled trial usage of the software, and highlight the importance of obtaining feedback from lesson participants. The recommendations seem to be straightforward and should help in formalising training with the program, as well as in the development of a network of teachers "accredited" to give lessons using the software.
Thomas Aquinas claimed that X's soul was X's only substantial form, although X also had numerous accidental forms that accounted for X's nonessential features. Aquinas defined a substantial form as that which makes X's matter constitute X, which in the case of a human being is also able to transcend the limitations of matter and establish both the rational capacity and natural immortality of human beings. Nevertheless, Aquinas did not claim that human persons were their disembodied souls because the human soul is essentially a substantial form activating matter into the body. He held that a proper human being is a composite of the rational soul and matter (both prime matter and individualized matter). So a soul separated from its body does not become an angel but retains its orientation to animate matter, while a corpse from which the soul has departed is not actually or potentially a human being. Eleonore Stump describes Aquinas' theory of the soul in terms of "configuration". The body is matter that is "configured", i.e. structured, while the soul is a "configured configurer". In other words, the soul is itself a configured thing, but it also configures the body. A dead body is merely matter that was once configured by the soul. It does not possess the configuring capacity of a human being. Aquinas believed that rational capacity was a property of the soul alone, not of any bodily organ. However, he did believe that the brain had some basic cognitive function.
== Transcriptomics == Different Hydra cell types express gene families of different evolutionary ages. Progenitor cells (stem cells, neuron and nematocyst precursors, and germ cells) express genes from families that predate metazoans. Among differentiated cells some express genes from families that date from the base of metazoans, like gland and neuronal cells, and others express genes from newer families, originating from the base of cnidaria or medusozoa, like nematocysts. Interstitial cells contain translation factors with a function that has been conserved for at least 400 million years.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.